Belimumab After Rituximab in Resistant Primary Juvenile SS

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Sjogren's SyndromePediatric ALL
Interventions
DRUG

Rituximab

Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L

DRUG

Belimumab

Belimumab every four weeks

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Children's Hospital of Chongqing Medical University

OTHER

collaborator

Central South University

OTHER

collaborator

Shenzhen Children's Hospital

OTHER_GOV

collaborator

The First Hospital of Jilin University

OTHER

collaborator

Children's Hospital of The Capital Institute of Pediatrics

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Children's Hospital of Nanjing Medical University

OTHER

collaborator

Children's Hospital of Fudan University

OTHER

collaborator

Shengjing Hospital

OTHER

collaborator

Shanghai Children's Hospital

OTHER

collaborator

Tianjin Children's Hospital

OTHER

lead

Peking Union Medical College Hospital

OTHER